Desteklenen Projeler
-
2017 - Devam Ediyor A randomized, multicenter, single dose, cross-over, double-blind study comparing the pharmacokinetic of biosimilar eptacog alfa with NovoSeven® in patients with congenital factor VII deficiency.
-
2017 - Devam Ediyor A prospective, phase 3, Open-label, International Multicetre Study on Efficiacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor (rVWF) in Severe Von Willebrand Disease
-
2017 - Devam Ediyor Hemofili hastalarında Profilaktik Tedavinin Eklem Sağlığı Üzerine Olan Koruyucu Etkisinin Gözlemlendiği, Çok Merkezli, Müdahalesiz, Gözlemsel İlaç Dışı Çalışma
-
2017 - Devam Ediyor Phase 3 prospective, multicenter, open label study to investigate safety, immunogenicity and hemostatic efficacy, of PEGylated Factor VIII (BAX855) in previously untreated patients (PUPs) <6 years with severe hemophilia A (FVIII<1%)
-
2017 - Devam Ediyor A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors
-
2017 - Devam Ediyor A phase 3, Prospective, Multicenter, Umcontrolled, Open-label Clinical Study to Determine the Efficiacy, Safety and Tolerability of Recombinant Von Willebrand Factor (rVWF) with or without ADVATE in Children Diagnosed with Severe von Willebrand Disease
-
2020 - 2026 An Open-label, Long-term Safety and Efficacy Study of Fitusiran in Patients with Hemophilia A or B, with or without Inhibitory Antibodies to Factor VIII or IX. Protokol:ATLAS-OLE.
-
2020 - 2023 An Open-Label, Multicenter Phase 2 Basket Study to Evaluate the Antitumor Activity and Safety of Lenvatinib in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Malignancies
-
2020 - 2023 Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
-
2015 - 2023 Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) 6 Years of Age With Severe Hemophilia A
-
2021 - 2022 Proflaksi tedavisi altındaki çocuk ve erişkin hemofili A hastalarında eklem sağlığını değerlendirmede HEAD-US ultrason eklem skorlama sisteminin öenminin araştırıldığı,ulusal,çok merkezli,kesitsel çalışma
-
2020 - 2022 Adeno-ilişkili virüs vektörü SPARK100 (BENEGENE-1) için nötrleştirici antikorlar açısından negatif olan, orta derecede ağır ila ağır hemofili B (FIX:C ≤%2) hastası olan yetişkin gönüllülerde ve adeno-ilişkili virüs vektörü SB-525 kapsidi (AAV6) için nötrleştirici antikorlar açısından negatif olan, ağır hemofili A (FVIII:C ≤%1) hastası olan yetişkin gönüllülerde, olağan bakım koşullarında halihazırda kullanılan FIX veya FVIII profilaksi replasman tedavisinin en az 6 aylık prospektif etkinliği ve seçili güvenlilik verilerinin değerlendirilmesi için açık etiketli, araştırma amaçlı ürün olmayan, çok merkezli değerlendirme çalışması
-
2019 - 2022 A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, without Inhibitory Antibodies to Factor VIII or IX
-
2019 - 2022 ATLAS-PPX: an Open-label, Multinational, Switching Study to Describe the Efficacy and Safety of Fitusiran Prophylaxis in Patients With Hemophilia A and B Previously Receiving Factor or Bypassing Agent Prophylaxis
-
2017 - 2018 b. A Phase 3, prospective, randomized, multi-center clinical study comparing the safety and efficacy of BAX 855 following PK-guided prophylaxis targeting two different FVIII trough levels in subjects with severe Hemophilia A
-
2015 - 2018 a. A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A.
-
2017 - 2017 SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) Study
-
2016 - 2017 e. A post Authorization Safety Surveillance Registry In Previously Untreated Patients with Severe Hemophilia A in Usual Care Settings
-
2013 - 2016 Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
-
2010 - 2016 An open label study of the safety and efficacy of refacto AF in previously untreated patients in usual care settings.
-
2009 - 2016 Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
-
2014 - 2015 A Phase III Open-label Pharmacokinetic, Efficacy and Safety Study of rVlll-Single Chain in a Pediatric Population with Severe Hemophilia A
-
2014 - 2015 d. Phase 3 prospective, uncontrolled, multicenter study evaluting pharmacokinetics, efficacy, safety, and immunogenicity of BAX855 (PEGylated full-length Recombinant FVIII )in previously treated pediatric patients with severe hemophilia A
-
2010 - 2015 a. SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) Study